Table 2.

P‐values with the corresponding fold changes of exosomal miRNAs in bold

Populations	Patient No.			miR‐16	miR‐21	miR‐23a	miR‐92a	miR‐93	miR‐100	miR‐126	miR‐200b	miR‐200c	miR‐223	miR‐320
EOC vs healthya	106 vs 29		Fold change	0.5	2.3	1.0	1.2	0.5	2.0	0.6	5.2	4.9	0.6	1.5
			P‐value	0.009	0.0001	1.000	0.148	0.014	0.034	0.012	0.008	0.143	0.029	0.034
EOC vs cystadenomaa	106 vs 8		Fold change	0.9	3.0	4.6	2.0	0.9	12.4	0.5	2.3	3.5	0.7	1.5
			P‐value	1.00	0.100	0.009	0.009	1.000	0.210	0.210	0.261	0.725	0.976	0.630
Cystadenoma vs healthya	8 vs 29		Fold change	0.6	0.8	0.2	0.6	0.6	0.2	1.1	2.3	1.4	0.9	1.0
			P‐value	0.478	0.839	0.008	0.034	0.770	0.177	1.000	0.229	1.000	1.000	1.000
Clinical parameters in EOC patients
Recurrencea	Yes	48	Fold change	0.5	1.1	1.0	0.8	0.6	1.4	1.0	1.3	1.1	0.8	0.9
	No	54	P‐value	0.001	0.648	0.845	0.073	0.05	0.224	0.780	0.710	0.841	0.366	0.717
Histologya	Serous	90	Fold change	0.7	0.5	0.7	0.7	0.7	0.6	0.7	0.7	0.6	0.7	0.7
	Others	13	P‐value	0.432	0.026	0.285	0.010	0.413	0.192	0.162	0.686	0.289	0.177	0.190
Gradinga	G1–2	24	Fold change	0.5	0.8	1.0	0.8	0.7	1.3	1.0	4.1	0.8	1.2	0.8
	G3	69	P‐value	0.019	0.504	0.995	0.150	0.200	0.341	0.946	0.144	0.524	0.366	0.226
CA125b			P‐value	0.325	0.377	0.637	0.124	0.415	0.156	0.762	0.002	0.003	0.835	0.363

^a P‐values are calculated by two‐tailed Student's t‐test. ^b P‐values are calculated by bivariate analyses of Spearman rho test.